Research institution
Institute of Cancer Research, United Kingdom Clinical Trials
Studies where Institute of Cancer Research, United Kingdom is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 24Adenocarcinoma
PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy
In radiotherapy high-tech scans with x-rays (CT scans) are taken before and during treatment to locate the tumour and ensure the radiation is hitting the target.
- Trial name
- NCT02973828
- Testing
- Imaging
- Where
- United Kingdom
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Triple Negative Breast Cancer
Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC
TILs have been shown to be predictive for response to neo-adjuvant chemotherapy in patients with TNBC in multiple studies (Level-1B evidence for clinical validity as per REMARK criteria).
- Trial name
- AIDOBE (NCT06396754)
- Testing
- AI-analysis on diagnostic and surgical specimens
- Volunteers
- 50 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa).
- Trial name
- GENPROS (NCT02705846)
- Testing
- Observation of treatment outcomes via Questionnaire
- Where
- United Kingdom
- Volunteers
- 4,260 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study
The BALANCE study is a prospective Patient Reported Outcomes Measures (PROMs) study developed to look at the quality of life (QoL) of patients diagnosed with prostate cancer (PCa) in communities underrepresented in research…
- Trial name
- BALANCE (NCT07529418)
- Testing
- Patient Reported Outcome Measurements (PROMs)
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer, Prostate Biopsy
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
Prostate cancer is now the most common cancer in men in the Western world. In the United Kingdom (UK), there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8.
- Conditions
- Prostate Cancer, Prostate Biopsy, Genetic Counselling, Genetic Markers
- Trial name
- PROFILE (NCT02543905)
- Testing
- Prostate MRI and Biopsy
- Where
- United Kingdom
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Melanoma (Skin Cancer), Non Small Cell Lung Cancer
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma.
- Conditions
- Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage
- Trial name
- BLAZE (NCT07718243)
- Testing
- Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ASpiRE (NCT07002320)
- Testing
- SX-682, Apalutamide
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Advanced Solid Tumours
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
The goal of this observational study is to attempt to find altered genetic 'switches' (mutations) in adults with advanced solid cancers who are being considered for, or are participating in, early-phase cancer clinical trials.
- Trial name
- MC2 (NCT07737509)
- Where
- 2 sites in United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Ovarian Cancer Recurrent
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and…
- Trial name
- SOPRANO (NCT05990192)
- Testing
- Niraparib oral capsule, SBRT
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)
5G-PEARL: Paxalisib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy.
- Trial name
- 5G-PEARL (NCT07391215)
- Testing
- Paxalisib, Temozolomide capsule
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Completed, with results posted
All 3Bladder Cancer
Study of Weekly Radiotherapy for Bladder Cancer
Background Localised muscle invasive bladder cancer (MIBC) is life-threatening and can cause significant symptoms. Around 50% of patients with MIBC who are referred for radiotherapy are unfit for standard radical treatment…
- Trial name
- HYBRID (NCT01810757)
- Testing
- Standard planning radiotherapy, Adaptive planning radiotherapy
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom